Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD

被引:71
作者
Dogra, Gursharan
Irish, Ashley
Chan, Dick
Watts, Gerald
机构
[1] Royal Perth Hosp, Sch Med & Pharmacol, Dept Nephrol, Perth, WA 6847, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia
[3] Western Australian Heart Res Inst, Perth, WA, Australia
关键词
chronic kidney disease (CKD); endothelial function; arterial compliance; dyslipidemia; insulin resistance; inflammation;
D O I
10.1053/j.ajkd.2006.08.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Conventional cardiovascular risk equations underestimate the risk for cardiovascular disease (CVD) in patients with chronic kidney disease (CKD), implying a role for novel risk factors. Our aim was to compare vascular function and arterial compliance, known markers of CVD, between patients with CKD and healthy controls and examine their association with traditional and novel CVD risk factors. Methods: Vascular function was determined by using high-resolution ultrasonography to measure brachial artery endothelial-dependent flow-mediated dilatation (FMD) and endothelial-independent glyceryl trinitrate (GTN)-mediated dilatation. Arterial compliance was measured by using pulse contour analysis to generate large-artery (Cl) and small-artery (C2) compliance. We also examined the relationship between vascular function, arterial compliance and blood pressure, lipid and lipoprotein levels, insulin resistance, inflammation, oxidative stress, and calcium and phosphate levels in 105 patients with CKD and 40 healthy controls. Results: Vascular function and arterial compliance were significantly impaired in patients with CKD compared with healthy controls: mean FMD, 3.8% +/- 0.3% (SE) versus 5.7% +/- 0.6%; GTN-mediated dilatation, 15.7% +/- 0.9% versus 19.6% +/- 1.0%; Cl, geometric mean, 12.1 mL/mm Hg; 95% confidence interval (Cl), 11.2 to 13.1 versus 15.1 mL/mm Hg; 95% Cl, 13.7 to 16.5; and C2,3.8 mL/mm Hg; 95% Cl, 3.4 to 4.3 versus 5.0 mL/mm Hg; 95% Cl, 4.2 to 6.0; all P < 0.05. Patients with CKD had greater waist-hip ratios, systolic blood pressures (SBPs), pulse pressures, triglyceride levels, oxidized low-density lipoprotein levels, high-sensitivity interleukin 6 levels, and Homeostasis Model Assessment (HOMA) scores (all P < 0.05) and lower high-density lipoprotein levels (P < 0.001). In patients with CKD, HOMA score and SBP were associated negatively with FMD (model R-2 = 0.28; P < 0.001), and SBP and waist-hip ratio were associated negatively with GTN-mediated dilatation (model R-2 = 0.25; P < 0.001). Pulse pressure was associated negatively with C1 (R-2 = 0.37; P < 0.001), and pulse pressure and high-sensitivity interleukin 6 level were associated negatively with C2 (model R-2 = 0.36; P < 0.001). Conclusion: Insulin resistance, inflammation, systolic hypertension, and increased pulse pressure, but not dyslipidemla, were associated with vascular dysfunction and may be targets for future interventional strategies to reduce CVD risk in patients with CKD.
引用
收藏
页码:926 / 934
页数:9
相关论文
共 53 条
[1]   Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis [J].
Adams, MR ;
Robinson, J ;
McCredie, R ;
Seale, JP ;
Sorensen, KE ;
Deanfield, JE ;
Celermajer, DS .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (01) :123-127
[2]   Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [J].
Al Suwaidi, J ;
Hamasaki, S ;
Higano, ST ;
Nishimura, RA ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 2000, 101 (09) :948-954
[3]   CLOSE RELATION OF ENDOTHELIAL FUNCTION IN THE HUMAN CORONARY AND PERIPHERAL CIRCULATIONS [J].
ANDERSON, TJ ;
UEHATA, A ;
GERHARD, MD ;
MEREDITH, IT ;
KNAB, S ;
DELAGRANGE, D ;
LIEBERMAN, EH ;
GANZ, P ;
CREAGER, MA ;
YEUNG, AC ;
SELWYN, AP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (05) :1235-1241
[4]   Impaired endothelium-dependent vasodilatation in renal failure in humans [J].
Annuk, M ;
Lind, L ;
Linde, T ;
Fellström, B .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 (02) :302-306
[5]   LIPOPROTEIN METABOLISM AND RENAL-FAILURE [J].
ATTMAN, PO ;
SAMUELSSON, O ;
ALAUPOVIC, P .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 21 (06) :573-592
[6]   Premature cardiovascular disease in chronic renal failure [J].
Baigent, C ;
Burbury, K ;
Wheeler, D .
LANCET, 2000, 356 (9224) :147-152
[7]   Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease [J].
Blacher, J ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
London, GM .
HYPERTENSION, 2001, 38 (04) :938-942
[8]   Aortic pulse wave velocity index and mortality in end-stage renal disease [J].
Blacher, J ;
Safar, ME ;
Guerin, AP ;
Pannier, B ;
Marchais, SJ ;
London, GM .
KIDNEY INTERNATIONAL, 2003, 63 (05) :1852-1860
[9]   NONINVASIVE DETECTION OF ENDOTHELIAL DYSFUNCTION IN CHILDREN AND ADULTS AT RISK OF ATHEROSCLEROSIS [J].
CELERMAJER, DS ;
SORENSEN, KE ;
GOOCH, VM ;
SPIEGELHALTER, DJ ;
MILLER, OI ;
SULLIVAN, ID ;
LLOYD, JK ;
DEANFIELD, JE .
LANCET, 1992, 340 (8828) :1111-1115
[10]   INSULIN RESISTANCE IN UREMIA [J].
DEFRONZO, RA ;
ALVESTRAND, A ;
SMITH, D ;
HENDLER, R ;
HENDLER, E ;
WAHREN, J .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 67 (02) :563-568